Testing the Ability to Decrease Chemotherapy in Patients with HER2-Positive Breast Cancer Who Have No Remaining Cancer at Surgery after Limited Pre-operative Chemotherapy and HER2-Targeted Therapy
Inclusion Criteria
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Patient must have histologically confirmed HER2-positive primary invasive breast carcinoma, determined by local testing. The tumor must have either HER2 immunohistochemistry (IHC) result of 3+ or HER2/CEP17 ratio > 2 with > 4.0 HER2 signals per cell by in situ hybridization (ISH). Tumors with HER2/CEP17 ISH ratio < 2 are ineligible, even if HER2 copy number is >= 6, unless HER2 IHC result is 3+
- Patients hormone receptor (ER and progesterone receptor [PR]) status must be known and will be determined by local testing. Patients with either hormone receptor –positive or hormone receptor- negative HER2-positive breast cancer are eligible
- Patients must have AJCC 8th edition stage II or IIIa according to anatomic staging table at diagnosis * Patients without nodal involvement (cN0) are eligible if T size > 2.0 cm (T2-3) * Patients with nodal involvement (cN1-2) are eligible if T1-3 * Patients with clinical T4 or N3 disease are not eligible
- Patient must be willing and able (i.e., have no contraindication) to receive standard adjuvant therapy, consisting of HER2-directed therapy, radiation (if indicated) and endocrine therapy (if ER+) if achieving pCR at surgery
- Patient with bilateral invasive breast cancers are eligible if both cancers are HER2-positive at least one meets protocol eligibility and neither cancer renders the patient ineligible
- Patients with multiple ipsilateral invasive tumors are eligible as long as all tumors are HER2-positive, and at least one tumor focus meets eligibility criteria. Multiple lesions that appear part of the same index tumor do not require additional biopsy/HER2 testing. However, even if biopsy is not deemed necessary, consideration should be given to placing a clip in any lesion that is 1 cm or further from the primary tumor to ensure that all tumor is removed at surgery AND that the pathologist can locate all primary sites of tumor to assess pathologic response at surgery
- Patients with a history of other non-breast malignancies are eligible if they have been disease-free for at least 5 years, and are deemed by the investigator to be at low risk for recurrence of that malignancy * Patients with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, basal cell or squamous cell carcinoma of the skin, and localized papillary or follicular thyroid cancer who have completed recommended treatment including surgery. Patients with any other cancers within the last 5 years are ineligible
- Patents must have a left ventricular ejection fraction (LVEF) within normal institutional parameters (or >= 50%)
- Patients must have a bilateral mammogram and a diagnostic breast ultrasound (on the side of the cancer[s]) (with or without breast magnetic resonance imaging [MRI]) performed at screening. An axillary ultrasound on the side of the cancer(s) is also required. However, if a patient has a negative axillary physical exam and a baseline MRI without suspicious lymph nodes performed before axillary ultrasound, axillary ultrasound may be omitted. Comprehensive breast and axillary imaging must be performed within 42 days of registration. (i.e. the patient’s mammogram/ breast ultrasound /axillary ultrasound OR their breast MRI)
- Baseline imaging of the ipsilateral axilla by ultrasound or breast MRI is mandatory. For subjects with axillary lymph node(s) suspicious on clinical exam or imaging, patient must be willing to have a needle aspiration or core biopsy to determine the presence of metastatic disease in the lymph nodes. A clip must be placed in the involved axillary lymph node. (If there are more than 1 suspicious axillary nodes, only one clipped node is required).
- Patient of childbearing potential and sexually active patients must use accepted and effective method(s) of contraception or to abstain from sexual intercourse for the duration of their participation in the study and for 7 months after the last dose of study treatment
- Patient must be willing and able to sign informed consent
- Leukocytes >= 3,000/mcL (obtained =< 28 days prior to protocol registration)
- Absolute neutrophil count >= 1,500/mcL (obtained =< 28 days prior to protocol registration)
- Platelets >= 100,000/mcL (obtained =< 28 days prior to protocol registration)
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (obtained =< 28 days prior to protocol registration)
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (obtained =< 28 days prior to protocol registration)
- Creatinine =< 1.5 x institutional ULN (obtained =< 28 days prior to protocol registration)
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Exclusion Criteria
- Patients must not have impaired decision-making capacity
- Patient must not have a history of any prior (ipsilateral or contralateral) invasive breast cancer * One exception: a patient with a history of T1N0 triple negative breast cancer diagnosed more than 10 years earlier, who remains disease free is eligible
- Patient must not have prior ipsilateral ductal breast carcinoma in situ (DCIS). Patients with prior lobular breast carcinoma in situ (LCIS), atypical hyperplasia, other high risk benign lesions or contralateral DCIS (without evidence of microinvasion) are eligible. Current ipsilateral or contralateral DCIS (diagnosed at the time of the current invasive cancer) is permitted * NOTE: Patients currently receiving endocrine therapy for prior contralateral DCIS are eligible
- Patient must not have stage IV (metastatic) breast cancer * Staging studies (computed tomography [CT] chest/abdomen/pelvis and a bone scan or positron emission tomography [PET]-CT scan) are required for stage III disease (according to AJCC cancer staging manual anatomic staging table, 8th edition) or those with abnormal baseline liver function tests (LFTs), symptoms (e.g., new bone pain) or abnormal physical exam findings (National Comprehensive Cancer Network [NCCN] guidelines version [V]1.2019)
- Patient must not have T4 and/or N3 disease, including inflammatory breast cancer
- Patient must not have any prior treatment for the current breast cancer, including surgery, chemotherapy, hormonal therapy, radiation or experimental therapy
- Patients must not have > grade 1 peripheral neuropathy of any etiology
- Patient must not have a concurrent serious medical condition that would preclude completion of study therapy. For example, uncontrolled hypertension (systolic > 180 mm Hg and/or diastolic > 100 mm Hg) or clinically significant (i.e., active) cardiovascular disease: cerebrovascular accident/stroke or myocardial infarction within 6 months prior to registration, unstable angina, congestive heart failure (CHF) or serious cardiac arrhythmia requiring medication and other concurrent serious diseases that may interfere with planned treatment
- Women must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. Patients must also not expect to conceive from the time of registration, while on study treatment, and until at least 7 months after the last dose of study treatment. All females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy * A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
Alabama
Birmingham
Alaska
Anchorage
Fairbanks
Arizona
Kingman
Phoenix
Tucson
Arkansas
Ft. Smith
Hot Springs
Jonesboro
California
Arroyo Grande
Auburn
Berkeley
Burbank
Burlingame
Cameron Park
Castro Valley
Davis
Dublin
Emeryville
Fremont
Huntington Beach
Los Angeles
Martinez
Marysville
Modesto
Mountain View
Newport Beach
Oakland
Orange
Palm Springs
Palo Alto
Pasadena
Roseville
Sacramento
Saint Helena
Salinas
San Francisco
San Jose
San Luis Obispo
Santa Cruz
Santa Maria
Santa Rosa
Sunnyvale
Truckee
Vacaville
Vallejo
Walnut Creek
Colorado
Aurora
Boulder
Centennial
Colorado Springs
Denver
Durango
Englewood
Fort Collins
Grand Junction
Greeley
Highlands Ranch
Lakewood
Littleton
Lone Tree
Longmont
Loveland
Parker
Pueblo
Thornton
Connecticut
Derby
Fairfield
Glastonbury
Greenwich
Guilford
Hartford
Meriden
New Britain
New Haven
North Haven
Orange
Stamford
Torrington
Trumbull
Waterbury
Waterford
Delaware
Frankford
Lewes
Newark
Rehoboth Beach
Seaford
Wilmington
District of Columbia
Washington
Florida
Altamonte Springs
Aventura
Celebration
Clearwater
Coral Gables
Deerfield Beach
Gainesville
Hollywood
Jacksonville
Kissimmee
Miami
Miami Beach
Orlando
Pembroke Pines
Plantation
Safety Harbor
Winter Haven
Winter Park
Georgia
Atlanta
Dalton
Duluth
Lawrenceville
Savannah
Snellville
Thomasville
Idaho
Boise
Caldwell
Coeur D'Alene
Emmett
Fruitland
Meridian
Nampa
Post Falls
Sandpoint
Twin Falls
Illinois
Alton
Aurora
Bloomington
Canton
Carbondale
Carterville
Carthage
Centralia
Chicago
Danville
Decatur
Dixon
Effingham
Eureka
Evanston
Galesburg
Glenview
Highland Park
Joliet
Kewanee
Lake Forest
Macomb
Mattoon
Mount Vernon
New Lenox
O'Fallon
Orland Park
Ottawa
Park Ridge
Pekin
Peoria
Peru
Princeton
Rockford
Silvis
Springfield
Swansea
Urbana
Washington
Yorkville
Indiana
Carmel
Indianapolis
Kokomo
Richmond
Iowa
Ames
Boone
Carroll
Cedar Rapids
Clive
Council Bluffs
Creston
Davenport
Des Moines
Fort Dodge
Jefferson
Marshalltown
West Des Moines
Kansas
Chanute
Dodge City
El Dorado
Garden City
Great Bend
Independence
Kingman
Liberal
Manhattan
McPherson
Newton
Parsons
Pratt
Salina
Wellington
Wichita
Winfield
Kentucky
Ashland
Bardstown
Corbin
Lexington
London
Louisville
Madisonville
Paducah
Shepherdsville
Louisiana
Covington
New Orleans
Shreveport
Maine
Augusta
Belfast
Biddeford
Brewer
Kennebunk
Rockport
Sanford
Scarborough
South Portland
Topsham
Maryland
Annapolis
Baltimore
Randallstown
Massachusetts
Beverly
Boston
Burlington
Gloucester
Lowell
Milford
Peabody
South Weymouth
Springfield
Winchester
Worcester
Michigan
Ann Arbor
Battle Creek
Brighton
Detroit
Farmington Hills
Grand Rapids
Kalamazoo
Muskegon
Niles
Norton Shores
Novi
Reed City
Saint Joseph
Southfield
Traverse City
Wyoming
Minnesota
Aitkin
Bemidji
Brainerd
Burnsville
Cambridge
Coon Rapids
Deer River
Detroit Lakes
Duluth
Edina
Fergus Falls
Fosston
Fridley
Hibbing
Maple Grove
Maplewood
Minneapolis
Monticello
New Ulm
Park Rapids
Princeton
Robbinsdale
Rochester
Saint Cloud
Saint Louis Park
Saint Paul
Sandstone
Shakopee
Stillwater
Thief River Falls
Virginia
Waconia
Willmar
Woodbury
Wyoming
Mississippi
Columbus
Grenada
Jackson
New Albany
Oxford
Pascagoula
Southhaven
Missouri
Ballwin
Bolivar
Branson
Cape Girardeau
Chesterfield
Columbia
Creve Coeur
Farmington
Jefferson City
Joplin
Rolla
Saint Joseph
Saint Louis
Saint Peters
Sainte Genevieve
Springfield
Sullivan
Sunset Hills
Washington
Montana
Anaconda
Billings
Bozeman
Great Falls
Kalispell
Missoula
Nebraska
Bellevue
Grand Island
Kearney
Lincoln
Omaha
Papillion
Nevada
Carson City
Henderson
Las Vegas
Pahrump
Reno
New Hampshire
Concord
Manchester
New Jersey
Basking Ridge
Hackensack
Hamilton
Jersey City
Lakewood
Livingston
Long Branch
Middletown
Montvale
Morristown
Mullica Hill
New Brunswick
Newark
Sewell
Somerville
Summit
Teaneck
Toms River
Vineland
New Mexico
Albuquerque
Las Cruces
Rio Rancho
New York
Auburn
Bronx
Brooklyn
Buffalo
Commack
East Hills
East Syracuse
Flushing
Glens Falls
Mineola
New York
Oneida
Oswego
Rochester
Stony Brook
Syracuse
Uniondale
Valley Stream
West Harrison
White Plains
North Carolina
Cary
Chapel Hill
Charlotte
Clinton
Garner
Goldsboro
Greensboro
Hendersonville
Hillsborough
Huntersville
Jacksonville
Kernersville
Matthews
Mooresville
Mount Airy
Pinehurst
Raleigh
Salisbury
Stateville
Thomasville
Wilkesboro
Winston-Salem
North Dakota
Bismarck
Fargo
Jamestown
Ohio
Alliance
Beavercreek
Boardman
Canton
Centerville
Cincinnati
Cleveland
Columbus
Dayton
Findlay
Franklin
Greenville
Kettering
Springfield
Steubenville
Troy
WPAFB
Warren
Youngstown
Oklahoma
Lawton
Oklahoma City
Oregon
Baker City
Bend
Clackamas
Coos Bay
Newberg
Ontario
Portland
Redmond
Pennsylvania
Altoona
Beaver
Butler
Camp Hill
Carlisle
Chadds Ford
Chambersburg
Cranberry Township
Danville
East Norriton
Ephrata
Erie
Farrell
Gettysburg
Greensburg
Greenville
Hanover
Harrisburg
Hazleton
Hershey
Indiana
Jefferson Hills
Johnstown
Lebanon
Lewisburg
Lewistown
McKeesport
Mechanicsburg
Monroeville
Moon Township
Mount Pleasant
Natrona Heights
New Castle
North Huntingdon
Philadelphia
Pittsburgh
Pottsville
Reading
Scranton
Selinsgrove
Seneca
State College
Uniontown
Washington
West Chester
West Mifflin
West Reading
Wexford
Wilkes-Barre
Williamsport
Willow Grove
York
Puerto Rico
Bayamon
Caguas
Manati
Ponce
San Juan
Rhode Island
Providence
Warwick
Westerly
South Carolina
Bluffton
Greenville
Hilton Head Island
South Dakota
Aberdeen
Sioux Falls
Tennessee
Bristol
Collierville
Franklin
Kingsport
Memphis
Nashville
Texas
Bryan
Dallas
Fort Worth
Houston
Laredo
Richardson
Utah
Farmington
Salt Lake City
South Jordan
Virginia
Bristol
Chesapeake
Gloucester
Mechanicsville
Midlothian
Newport News
Norfolk
Norton
Portsmouth
Richmond
South Hill
Suffolk
Virginia Beach
Williamsburg
Washington
Aberdeen
Bellevue
Bellingham
Bremerton
Burien
Centralia
Edmonds
Enumclaw
Everett
Federal Way
Issaquah
Kennewick
Lacey
Lakewood
Longview
Port Townsend
Poulsbo
Renton
Seattle
Sedro-Woolley
Shelton
Tacoma
Vancouver
Walla Walla
Yakima
Yelm
West Virginia
Charleston
Wisconsin
Antigo
Appleton
Ashland
Brookfield
Burlington
Chilton
Chippewa Falls
Cudahy
Eau Claire
Franklin
Germantown
Grafton
Green Bay
Hayward
Johnson Creek
Kenosha
La Crosse
Ladysmith
Madison
Marinette
Marshfield
Medford
Mequon
Milwaukee
Minocqua
Neenah
New Richmond
Oconto Falls
Oshkosh
Racine
Rhinelander
Rice Lake
Sheboygan
Spooner
Stevens Point
Sturgeon Bay
Summit
Superior
Two Rivers
Wausau
Wauwatosa
West Allis
Weston
Wisconsin Rapids
Wyoming
Cheyenne
Cody
Sheridan
PRIMARY OBJECTIVES:
I. To determine if 3-year recurrence-free survival (RFS) is greater than 92% among clinical stages II or IIIa patients (by American Joint Committee on Cancer [AJCC] cancer staging manual anatomic staging table, 8th edition) with HER2-positive/ER-positive breast cancer who achieve pathologic complete response (pCR) (ypT0/is ypN0) after preoperative therapy with 12 weeks of a taxane, trastuzumab (or Food and Drug Administration [FDA] approved biosimilar) and pertuzumab (THP x 12). Post-operatively, patients will receive standard of care adjuvant locoregional therapy, plus completion of 12 months of HER2-targeted therapy (and standard adjuvant endocrine therapy for patients with estrogen receptor-positive disease).
II. To determine if 3-year recurrence-free survival (RFS) is greater than 92% among clinical stages II or IIIa patients (by AJCC cancer staging manual anatomic staging table, 8th edition) with HER2-positive/ER-negative breast cancer who achieve pCR (ypT0/is ypN0) after preoperative therapy with 12 weeks of a taxane, trastuzumab (or FDA approved biosimilar) and pertuzumab (THP x 12). Post-operatively, patients will receive standard of care adjuvant locoregional therapy, plus completion of 12 months of HER2-targeted therapy (and no adjuvant endocrine therapy for patients with estrogen receptor-negative disease).
SECONDARY OBJECTIVES:
I. To determine 3-year IDFS (invasive disease-free survival), DDFS (distant disease-free survival), DRFS (distant relapse-free survival), RFI (recurrence-free interval), OS (overall survival) and breast cancer-specific survival in patients who achieve pCR (and by pretreatment clinical stage). (Secondary Clinical Objective)
II. To determine 3-year EFS (event-free survival) in all patients from time of study registration. (Secondary Clinical Objective)
III. To evaluate safety and tolerability for all patients during the pre-operative phase and for patients who attain pCR and de-escalate therapy (Arm A) until the completion of post-surgery protocol assigned therapy (i.e., until the end of trastuzumab and pertuzumab [HP] therapy). (Secondary Clinical Objective)
IV. To evaluate the association of estrogen receptor (ER) status in the untreated primary tumor with pathologic response and with long-term survival outcomes (including RFS, EFS, IDFS, DDFS, DRFS, RFI, OS, and breast cancer-specific survival). (Secondary Correlative Objective)
V. To evaluate the associations of detection of circulating tumor cells (CTCs) in the blood at baseline with pCR. (Secondary Correlative Objective)
VI. To evaluate the association of detection of CTCs in the blood at baseline, after 3 weeks of THP, after 12 weeks of THP (before surgery), after surgery before any additional therapy, and after completion of HER2-targeted therapy with RFS in patients who achieve pCR or not. (Secondary Correlative Objective)
EXPLORATORY OBJECTIVES:
I. To determine 3-year RFS, IDFS (invasive disease-free survival), DDFS (distant disease-free survival), DRFS (distant relapse-free survival), RFI (recurrence-free interval), OS (overall survival) and breast cancer-specific survival in patients who do not achieve pCR (and by pretreatment clinical stage). (Exploratory Clinical Objective)
II. To determine the pathologic response to THP neoadjuvant therapy, as assessed by residual cancer burden (RCB). (Exploratory Clinical Objective)
III. To determine the association between residual cancer burden (RCB) and all described standardized definitions for efficacy end points (STEEP) criteria outcomes. (Exploratory Clinical Objective)
IV. To determine the false negative rate (FNR) of limited staging procedures (defined as sentinel lymph node biopsy [SLNB] plus removal of clipped node) in patients who undergo such procedures with a planned axillary lymph node dissection (ALND). (Exploratory Clinical Objective)
V. To determine axillary pCR rates as a function of the burden of disease at presentation as determined on pre-treatment ultrasound (US) and the axillary staging technique (SLNB plus ensuring removal of clipped node versus ALND). (Exploratory Clinical Objective)
VI. To evaluate the associations between plasma tumor cell-free deoxyribonucleic acid (DNA) (cfDNA) tumor-specific mutations (baseline and after therapy) with pathologic response and long-term outcomes (including RFS, EFS, IDFS, DDFS, DRFS, RFI, OS, and breast cancer-specific survival). (Exploratory Correlative Objective)
VII. To evaluate the associations between tumor infiltrating lymphocytes (TILs) in the baseline tumor with pathologic and long-term outcomes (including RFS, EFS, IDFS, DDFS, DRFS, RFI, OS and breast cancer-specific survival) and in the residual tumor with long-term outcomes. (Exploratory Correlative Objective)
VIII. To evaluate the associations between immune activation gene signatures in the baseline tumor and pathologic response as well as outcomes (including RFS, EFS, IDFS, DDFS, DRFS, RFI, OS and breast cancer-specific survival). (Exploratory Correlative Objective)
IX. To evaluate the association of intrinsic subtype at baseline with outcomes (pathologic response and survival). (Exploratory Correlative Objective)
X. To determine the frequency of change in intrinsic subtype between pretreatment tumor specimen and residual disease at the time of surgery and to evaluate any association with survival. (Exploratory Correlative Objective)
XI. To evaluate the associations between DNA copy number, DNA mutations, ribonucleic acid (RNA) expression and protein expression in the baseline tumor and changes from baseline to post-THP therapy with pathologic response and long-term outcomes (including RFS, EFS, IDFS, DDFS, DRFS, RFI, OS, and breast cancer-specific survival). (Exploratory Correlative Objective)
OUTLINE:
PRE-OPERATIVE/NEOADJUVANT THERAPY: Patients receive either paclitaxel or nab-paclitaxel intravenously (IV) on days 1, 8 and 15, or docetaxel IV on day 1 at the discretion of the treating oncologist. Patients also receive trastuzumab IV on day 1 and weekly thereafter, and pertuzumab IV on day 1. Patients may substitute trastuzumab-hyaluronidase subcutaneously (SC) over 2-5 minutes on day 1 in place of trastuzumab or pertuzumab-trastuzumab-hyaluronidase SC over 8 minutes on day 1 of cycle 1 and over 5 minutes on day 1 of cycles 2-4 in place of trastuzumab and pertuzumab. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. However, if surgery occurs later than 21 days after the 4th cycle of trastuzumab and pertuzumab, patients receive an additional cycle of trastuzumab and pertuzumab before surgery.
SURGERY: Within 126 days (18 weeks) after the first dose of neoadjuvant therapy, patients undergo standard of care lumpectomy and/or mastectomy.
POST-OPERATIVE/ADJUVANT THERAPY: Patients are assigned to 1 of 2 arms.
ARM A: Patients with pCR after surgery receive trastuzumab and pertuzumab IV on day 1. Patients may substitute trastuzumab-hyaluronidase SC over 2-5 minutes on day 1 in place of trastuzumab or pertuzumab-trastuzumab-hyaluronidase SC over 5 minutes on day 1 in place of trastuzumab and pertuzumab. Treatment repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo standard of care radiation therapy and receive hormone therapy if appropriate.
ARM B: Patients with remaining tumor after surgery receive standard of care trastuzumab emtansine for 14 doses in the absence of disease progression or unacceptable toxicity. Patients may also receive additional standard of care chemotherapy, as well as hormone therapy if appropriate.
After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 2-5 years, then annually for 5-15 years from date of surgery.
Trial Phase Phase II
Trial Type Treatment
Lead Organization
ECOG-ACRIN Cancer Research Group
Principal Investigator
Nadine Muskatel Tung
- Primary ID EA1181
- Secondary IDs NCI-2019-07439
- Clinicaltrials.gov ID NCT04266249